StockData
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC (ADAPY) stock

ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30
$0.04+0.00 (+9.38%)

Close on Oct 19, 2026Market cap $55.46MP/E –Yield –

Adaptimmune Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Adaptimmune Therapeutics's free cash flow for the twelve months ending Jun 30, 2025 was -$191.67M. For fiscal 2024 it was -$74.09M. The highest annual figure on record is $35.47M in fiscal 2014.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$74.09M–
FY2023Dec 31, 2023-$145.56M–
FY2022Dec 31, 2022-$171.27M-8047.3%
FY2021Dec 31, 2021$2.16M–
FY2020Dec 31, 2020-$55.93M–
FY2019Dec 31, 2019-$114.10M–
FY2018Dec 31, 2018-$108.30M–
FY2017Dec 31, 2017-$78.96M–
FY2015Jun 30, 2015-$34.75M-198.0%
FY2014Jun 30, 2014$35.47M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2025CQ2 2025Jun 30, 2025-$34.86M-174.2%
Q1 FY2025CQ1 2025Mar 31, 2025-$67.80M–
Q4 FY2024CQ4 2024Dec 31, 2024-$34.42M–
Q3 FY2024CQ3 2024Sep 30, 2024-$54.59M–
Q2 FY2024CQ2 2024Jun 30, 2024$46.98M–
Q1 FY2024CQ1 2024Mar 31, 2024-$32.05M–
Q4 FY2023CQ4 2023Dec 31, 2023-$15.50M–
Q3 FY2023CQ3 2023Sep 30, 2023-$45.45M–
Q2 FY2023CQ2 2023Jun 30, 2023-$44.98M–
Q1 FY2023CQ1 2023Mar 31, 2023-$39.63M–
Q4 FY2022CQ4 2022Dec 31, 2022-$1.37M-101.1%
Q3 FY2022CQ3 2022Sep 30, 2022-$58.17M–
Q2 FY2022CQ2 2022Jun 30, 2022-$50.21M–
Q1 FY2022CQ1 2022Mar 31, 2022-$61.52M–
Q4 FY2021CQ4 2021Dec 31, 2021$129.91M–
Q3 FY2021CQ3 2021Sep 30, 2021-$46.83M–
Q2 FY2021CQ2 2021Jun 30, 2021-$33.23M–
Q1 FY2021CQ1 2021Mar 31, 2021-$47.69M-386.2%
Q4 FY2020CQ4 2020Dec 31, 2020-$30.38M–
Q3 FY2020CQ3 2020Sep 30, 2020-$17.03M–
Q2 FY2020CQ2 2020Jun 30, 2020-$25.18M–
Q1 FY2020CQ1 2020Mar 31, 2020$16.67M–
Q4 FY2019CQ4 2019Dec 31, 2019-$12.70M–
Q3 FY2019CQ3 2019Sep 30, 2019-$29.83M-422.3%
Q2 FY2019CQ2 2019Jun 30, 2019-$34.47M–
Q1 FY2019CQ1 2019Mar 31, 2019-$37.11M–
Q4 FY2018CQ4 2018Dec 31, 2018-$31.77M–
Q3 FY2018CQ3 2018Sep 30, 2018$9.26M-22.1%
Q2 FY2018CQ2 2018Jun 30, 2018-$36.60M–
Q1 FY2018CQ1 2018Mar 31, 2018-$49.18M–
Q4 FY2017CQ4 2017Dec 31, 2017-$23.21M–
Q3 FY2017CQ3 2017Sep 30, 2017$11.89M–
Q2 FY2017CQ2 2017Jun 30, 2017-$26.95M–
Q1 FY2017CQ1 2017Mar 31, 2017-$40.69M–
Q3 FY2015CQ1 2015Mar 31, 2015-$6.32M–

More Adaptimmune Therapeutics figures

See a number that looks wrong?